Cantor Fitzgerald initiated coverage on NexImmune with a new price target
$NEXI
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald initiated coverage of NexImmune with a rating of Overweight and set a new price target of $35.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/22/2022 | $21.00 → $13.00 | Outperform | Raymond James |
| 11/15/2021 | $30.00 → $21.00 | Outperform | Raymond James |
SC 13D - NexImmune, Inc. (0001538210) (Subject)
SC 13G/A - NexImmune, Inc. (0001538210) (Subject)
SC 13G/A - NexImmune, Inc. (0001538210) (Subject)
25-NSE - NexImmune, Inc. (0001538210) (Subject)
EFFECT - NexImmune, Inc. (0001538210) (Filer)
S-8 POS - NexImmune, Inc. (0001538210) (Filer)
Company has initiated pre-IND discussions with the FDA for its first AIM INJ indicationNEXI-001 completed enrollment in its final safety cohorts and all patients have been dosed; Company continues to follow patients and will announce data at or around an upcoming scientific conferenceCompany announces executive management changes as part of resource reallocation GAITHERSBURG, Md., March 28, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today reported financial results for t
Company announces a strategic shift to focus on advancing its AIM Direct Injection (AIM INJ) platform and potential product candidates in oncology and autoimmune diseasesInitiating a corporate resource reallocation to advance the AIM INJ platform, reduce operating expenses and extend cash runway through the third quarter of 2023 Pausing enrollment and initiation for the NEXI-001 and NEXI-003 trials, respectively, and pursuing external clinical development through potential academic and corporate partners GAITHERSBURG, Md., Nov. 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted
Received U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) submission for NEXI-003, the Company's first solid tumor product candidate for the treatment of HPV-related cancersPlans to report additional preclinical and IND enabling data for the AIM Injectable platform in 2H22Clinical updates for the Company's two lead product candidates in Phase 1/2 clinical trials expected in 4Q22Company is prioritizing resources to support Company's lead product candidates, NEXI-001 and NEXI-003 GAITHERSBURG, Md., Aug. 15, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed t
Raymond James reiterated coverage of NexImmune with a rating of Outperform and set a new price target of $13.00 from $21.00 previously
Raymond James reiterated coverage of NexImmune with a rating of Outperform and set a new price target of $21.00 from $30.00 previously
Raymond James initiated coverage of NexImmune with a rating of Outperform and set a new price target of $30.00
Gainers Sharps Technology (NASDAQ:STSS) stock increased by 56.5% to $0.4 during Wednesday's after-market session. The market value of their outstanding shares is at $6.3 million. Geovax Labs (NASDAQ:GOVX) shares moved upwards by 21.71% to $2.27. The market value of their outstanding shares is at $5.2 million. NexImmune (NASDAQ:NEXI) stock increased by 9.52% to $3.45. The company's market cap stands at $4.7 million. As per the news, the Q1 earnings report came out 2 days ago. Cognition Therapeutics (NASDAQ:CGTX) stock rose 8.04% to $2.83. The market value of their outstanding shares is at $113.3 million. Clearside Biomedical (NASDAQ:CLSD) shares rose 7.39% to $1.45. The market value of t
Gainers Lucy Scientific Discovery (NASDAQ:LSDI) stock moved upwards by 123.5% to $1.14 during Thursday's pre-market session. The market value of their outstanding shares is at $2.0 million. SINTX Techs (NASDAQ:SINT) stock moved upwards by 19.67% to $0.15. The market value of their outstanding shares is at $18.7 million. As per the press release, Q1 earnings came out 3 days ago. Dynatronics (NASDAQ:DYNT) stock increased by 16.7% to $0.51. The market value of their outstanding shares is at $2.7 million. Ontrak (NASDAQ:OTRK) shares moved upwards by 15.99% to $0.31. The company's market cap stands at $14.8 million. The company's, Q1 earnings came out 2 days ago. NovaBay Pharmaceuticals (AME
4 - NexImmune, Inc. (0001538210) (Issuer)
GAITHERSBURG, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced the closing of its previously announced registered direct offering of 304,731 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company also issued unregistered warra
GAITHERSBURG, Md., Feb. 02, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that it has entered into a definitive agreement with a single healthcare focused institutional investor for the issuance and sale of an aggregate of 304,731 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq ru
A JDRF funded grant is being used to explore the combination of NexImmune's antigen specific nanoparticles and an anti-CD3 mAb for prevention and treatment of type 1 diabetes GAITHERSBURG, Md., Oct. 24, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI) announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune's AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells. The extension includes an additional $300,000 grant, funded by JDRF to Yale, as a part of its Cures research portfolio, which includes therapies for the prevention of type 1 diabetes (T1D). "We
4 - NexImmune, Inc. (0001538210) (Issuer)
3 - NexImmune, Inc. (0001538210) (Issuer)
4 - NexImmune, Inc. (0001538210) (Issuer)
Clinical data updates for the Company's two lead product candidates in Phase 1/2 clinical trials expected in 2H2022Investigational New Drug (IND) submission for NEXI-003, the Company's first product for solid tumors, planned for 1H2022Plans to report additional preclinical and IND enabling data for the AIM Injectable platform in 2H2022 GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported financial results for the first quarter of 2022. "This quarter, we hav
GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the appointment of Leena Gandhi, M.D., Ph.D., Director for the Center of Therapeutic Innovation at Dana-Farber Cancer Institute, to its Board of Directors as a Non-Executive Director. "I am honored to join the board of NexImmune at this pivotal juncture in the Company's work," stated Dr. Gandhi. "I am excited to work with NexImmune's leadership on maximizing the potential of its novel technology in multip
GAITHERSBURG, Md., Feb. 17, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Kristi Jones has been appointed as the Company's Chief Executive Officer and a member of its Board of Directors. Her appointment follows the departure of Scott Carmer, who submitted his letter of resignation this week. "The Board is pleased to appoint Kristi Jones as our new Chief Executive Officer and member of the Board of Directors," said Sol J. Barer, Chairman of NexImmune's Board of Directors.